The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Clicks: 241
ID: 271796
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #12 of 30 articles by views in Pharmaceuticals (Basel, Switzerland)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Elderly transplant-ineligible (NTE) patients represent the majority of patients affected by multiple myeloma (MM). Elderly patients are a highly heterogeneous population, with large variability in health and functional status. Thus, choosing their optimal treatment is challenging. A wide range of fi …
Reference Key
f2020pharmaceuticalsthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bonello F;Grasso M;D'Agostino M;Celeghini I;Castellino A;Boccadoro M;Bringhen S;;
Journal Pharmaceuticals (Basel, Switzerland)
Year 2020
DOI
DOI not found
URL
https://www.pubmed.gov/33383757/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review pubmed abstract nih national institutes of health national library of medicine sara bringhen pmid:33383757 pmc7823261 doi:10.3390/ph14010020 francesca bonello mariella grasso

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.